Femara

Femara

letrozole

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Letrozole
Indications/Uses
Adjuvant treatment of postmenopausal women w/ hormone receptor positive early breast cancer. Extended adjuvant treatment of early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy. 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Advanced breast cancer in women w/ natural or artificially induced postmenopausal status, who have previously been treated w/ antiestrogens.
Dosage/Direction for Use
Adult & elderly: 2.5 mg once daily.
Administration
May be taken with or without food.
Contraindications
Premenopausal endocrine status. Pregnancy & lactation.
Special Precautions
Patients w/ CrCl <10 mL/min; severe hepatic impairment (Child-Pugh score C). Monitor bone health. May impair ability to drive or operate machinery.
Adverse Reactions
Hot flushes, nausea, fatigue, arthralgia. Anorexia, increased appetite, hypercholesterolemia, depression, headache, dizziness, vomiting, dyspepsia, constipation, diarrhoea, alopecia, increased sweating, rash, myalgia, bone pain, osteoporosis, bone fractures, peripheral oedema, wt increase.
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Femara film-coated tab 2.5 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in